Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Parallel-group Exploratory Clinical Trial to Evaluate the Safety and Preliminary Efficacy of Recombinant Human Serum Albumin Injection in the Treatment of Mild-to-moderate Alzheimer's Disease

NCT06489015 is registered in ClinicalTrials.gov with Shenzhen Protgen Co., Ltd. as lead sponsor.

NCT NCT06489015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06489015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Parallel-group Exploratory Clinical Trial to Evaluate the Safety and Preliminary Efficacy of Recombinant Human Serum Albumin Injection in the Treatment of Mild-to-moderate Alzheimer's Disease
Lead sponsor
Shenzhen Protgen Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
August 27, 2024
Completion date
April 14, 2026
Enrollment
30 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease (ad)